Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Janne is the Director of the Lowe Center for Thoracic Oncology, the Director of the Belfer Center for Applied Cancer Science and the Director of the Chen-Huang Center for EGFR Mutant Lung Cancers.  He is a Senior Physician at Dana Farber Cancer Institute and Professor of Medicine at Harvard Medical School.  

 

2020 TTF AM SESSION - JANNE - Insights Into Acquired Resistance: the Role of Repeat Biopsies
2020 Targeted Therapies Patient Forum AM Session - Dr. Pasi Janne - Insights Into Acquired Resistance and the Role of Repeat Biopsies
Author
Pasi Janne, MD, PhD GRACE Faculty
Image
We are excited to be able to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum.

This year's live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute.

This day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer.

Access to the full agenda can be found here: https://drive.google.com/file/d/10sk1Are37fCIHcc6laD6lh9m_DjLF1ZX/view?u....

Full bios for attending faculty can be found here: https://docs.google.com/document/d/1EQEmBpOI-vNIywsFPEIhizql_Xnzjcf5-mua....

 
In this video from the AM Session of the event, Dr. Pasi Janne examines insights into acquired resistance and the role of repeat biopsies.

We thank our sponsors for their support of this event! AstraZeneca, Lilly, Novartis, Takeda, Foundation Medicine, Boehringer Ingelheim, Blueprint Medicines and Genentech

 

To join the conversation, visit https://cancergrace.org/forum.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora